ADC Therapeutics SA
NYSE:ADCT
Net Margin
ADC Therapeutics SA
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | Company | Market Cap |
Net Margin |
||
---|---|---|---|---|---|
CH |
ADC Therapeutics SA
NYSE:ADCT
|
176.9m USD |
-297%
|
||
FR |
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
||
US |
Abbvie Inc
NYSE:ABBV
|
303.2B USD |
9%
|
||
US |
Amgen Inc
NASDAQ:AMGN
|
146.3B USD |
13%
|
||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
114.4B USD |
0%
|
||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.8B USD |
-5%
|
||
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
AU |
CSL Ltd
ASX:CSL
|
132.7B AUD |
18%
|
||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
75B USD |
34%
|
||
US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
|
NL |
argenx SE
XBRU:ARGX
|
38.1B EUR |
-5%
|
ADC Therapeutics SA
Glance View
ADC Therapeutics SA is a clinical-stage biotechnology company. The company is headquartered in Epalinges, Vaud and currently employs 312 full-time employees. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on ADC Therapeutics SA's most recent financial statements, the company has Net Margin of -297.3%.